Navigation Links
LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
Date:9/16/2010

BOZEMAN, Mont., Sept. 16 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company focused on the development of innovative vaccine products, announced today that it has initiated the first clinical trial for its bivalent intramuscular (IM) norovirus vaccine candidate, marking the fourth human clinical trial in the Company's norovirus virus-like particle (VLP) vaccine program.  The Phase I dose-escalation study will assess safety and immunogenicity associated with an IM formulation of LigoCyte's investigational vaccine in healthy adults. Clinical studies to date have shown a nasal formulation of a monovalent norovirus VLP vaccine to be immunogenic (i.e., having the ability to create an immune response) and generally well tolerated.

The bivalent vaccine formulation involved in the trial includes antigens from both norovirus genogroups that commonly infect humans. LigoCyte's bivalent vaccine is designed to provide protection against group I noroviruses with its GI.1 VLP antigen and against group II noroviruses with its GII.4 VLP antigen. Genogroup II.4 noroviruses are responsible for the majority of norovirus disease worldwide.  

"Norovirus infections are recognized as a widespread problem that can have very serious consequences," said Donald P. Beeman, CEO of LigoCyte.  "This bivalent norovirus vaccine is the first to be tested clinically, and the first GII.4 subtype antigen to be included in a human vaccine. Study of an intramuscular norovirus vaccine will continue to advance our norovirus program, which has been built on a nasally administered dry powder formulation. We have shown excellent results with the nasal vaccine to date, and investigation of multiple routes of administration will help us to select the best possible form of the product to prevent the burden of disease associated with this highly contagious virus."

LigoCyte plans to enroll 98 subjects in the study across three cohorts. Initial study sites are the University of Rochester and Saint Louis University.  

Norovirus infection, well known as the "stomach flu," is the most common cause of acute gastroenteritis, afflicting nearly 23 million Americans annually.  Norovirus infection is characterized by the acute onset of nausea, vomiting, abdominal cramps, diarrhea, and occasionally fever. Noroviruses are highly infective and easily transmitted. Epidemic outbreaks occur in community environments, particularly hospitals, hotels, schools, and nursing homes, resulting in significant risk to immunocompromised individuals and mounting socioeconomic cost to families, the health care system and businesses.  Military units are also affected, as outbreaks represent a significant readiness issue for naval vessels and land-based installations. Severe clinical outcomes are associated with particular at-risk populations, where complications caused by infection can disrupt primary treatment regimens and even lead to death.

LigoCyte's norovirus vaccine franchise is based on VLP antigens, which are highly purified protein products.  By preserving the authentic conformation of the viral capsid, VLPs mimic the antigens as they exist on the live virus while lacking the ability to reproduce or cause illness.  LigoCyte's vaccine formulations also include the adjuvant Monophosphoryl Lipid A, provided under license from GlaxoSmithKline (NYSE: GSK).  Additional information about the study can be found at www.clinicaltrials.gov.

About LigoCyte

LigoCyte is a private, clinical-stage biopharmaceutical company focused on developing novel vaccines for gastrointestinal and respiratory indications. LigoCyte's expertise in virus-like particle technology supports a pipeline of enhanced product candidates, including vaccines against norovirus, influenza and respiratory syncytial virus. LigoCyte has funded its product development efforts through a mix of private investment as well as grants and contracts administered through the National Institutes of Health and the U.S. Department of Defense, including a recent $3.6 million commitment from the agency. LigoCyte's investors include Forward Ventures, JAFCO, Novartis Venture Fund, Fidelity Biosciences, MedImmune Ventures, Athenian Venture Partners and MC Life Sciences Ventures (Mitsubishi International Corporation). The company closed its most recent financing in April 2010 from its existing venture investors. GlaxoSmithKline is also a shareholder of the company. For additional information on LigoCyte, please visit www.ligocyte.com.


'/>"/>
SOURCE LigoCyte Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
2. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
3. Data From LigoCytes Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)...  Results from the Phase II SUSTAIN study show ... the median annual rate of sickle cell-related pain crises ... p=0.010) in patients with or without hydroxyurea therapy 1 ... featured in the official press briefing at the 58 ... and presented during the Plenary Scientific Session tomorrow (Abstract ...
Breaking Medicine Technology:
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... Washington DC (PRWEB) , ... December 04, 2016 , ... ... Environmental, one of the most certified and experienced Indoor Air Quality Companies in VA, ... Assessment and Remediation Regulations. , The new mold law in the district ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine ... San Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in ... and beyond the standard of care, demonstrating leadership within the MPN community and/or a ...
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... California, will be included in the 2016 “Guide to America’s Top Plastic Surgeons” ... on the amalgamation of their education, experience, and professional associations. , One ...
Breaking Medicine News(10 mins):